Genscript Biotech Corporation (OTCPK:GNNSF) Q2 2025 Earnings Conference Call August 17, 2025 7:00 PM ET
Company Participants
Aixi Bai – General Manager of Bestzyme
Allen Guo – CEO of ProBio
Josie Zhou – Interim CFO
Ray Chen – President of GenScript Life Science Group
Weihui Shao – CEO & COO
Conference Call Participants
Daisy Cheng – Morgan Stanley, Research Division
Wai Chak Yuen – Daiwa Securities Co. Ltd., Research Division
Wanhua Wu – China International Capital Corporation Limited, Research Division
Yang Huang – JPMorgan Chase & Co, Research Division
Good day and thank you for standing by. Welcome to Genscript Biotech 2025 Interim Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there’ll be question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded..
I would now like to hand the conference over to your first speaker today, CFO, Josie Zhou. Please go ahead.
Josie Zhou
Hello, everyone. This is Josie Zhou, Interim CFO at GenScript. Welcome to our 2025 interim results conference call. Joining on the call today are Mr. Robin Meng, Chairman of the Board; Ms. Sherry Shao, Rotating CEO of GenScript; Dr. Ray Chen, President of GenScript Life Science Group; Dr. Aixi Bai, General Manager of Bestzyme; Mr. Allen Guo, CEO of ProBio.
During today’s call, we will be making statements about future expectations, plans and the prospects as well as any other statements regarding matters that are not historical facts, which may consider forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements because of various important risk effects and the changing market conditions. We do not undertake any obligation to publicly update any forward-looking statements.
Today, Sherry will start with the company overview and our business head will present the first
#Genscript #Biotech #Corporation #GNNSF #Earnings #Call #Transcript